Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Gains from Investment Securities (2016 - 2025)

CorMedix's Gains from Investment Securities history spans 13 years, with the latest figure at -$2.0 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 430.64% year-over-year to -$2.0 million; the TTM value through Dec 2025 reached -$252000.0, down 83.94%, while the annual FY2025 figure was -$252000.0, 83.94% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$2.0 million at CorMedix, down from $464088.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $25.4 million in Q1 2023 and bottomed at -$6.7 million in Q3 2021.
  • The 5-year median for Gains from Investment Securities is $2.3 million (2021), against an average of $4.5 million.
  • The largest YoY upside for Gains from Investment Securities was 949.23% in 2025 against a maximum downside of 430.64% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $14.4 million in 2021, then plummeted by 38.91% to $8.8 million in 2022, then soared by 189.77% to $25.4 million in 2023, then crashed by 101.47% to -$373615.0 in 2024, then tumbled by 430.64% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Gains from Investment Securities are -$2.0 million (Q4 2025), $464088.0 (Q3 2025), and $247484.0 (Q2 2025).